RE: all talk about the treatment is21 Feb 2019 05:57
I'm sorry but the ATs affect LTHs too! They are the reason any previous SP rise since the Nasdaq listing was quashed so none of us could comfortably derisk before D Day. They have clearly kept the SP range bound and stopped any rerate even after both successful P3 trials and then the NDA submission etc.
Just think about that for a moment, even after two successful P3 trials and an NDA submission - the first of any company on AIM for a long time, the SP reached near an ATL just a couple of months before d day! - and all orchestrated by the ATs (whatever or whoever is behind them).
Who knows, if the SP had hit around 70p where I firmly believe it deserved to be after the P3 results then perhaps Motif would have been in a much better position to do a pre-decision raise, just in case, and we wouldn't be in the funding mess we're in now.
The ATs also crushed last week's recovery to 15p. You can blame traders but I've been watching those trades closely for a long time. 'Nonethewiser' is the only other poster to have consistently mentioned this but nobody seems to listen. Am not sure why, surely the SP is important to us as investors no?!?
No other share I know of out of over 200 I've chacked has even a fraction of the ATs we've had here. And no other share has it's SP solely decided by the latest AT (for as little as a few quid's worth at times) regardless of ALL the other trades going on.
As NTW said when he called in to the CC, it needs investigating. The BoD seemed aloof to his question. Obviously they couldn't comment directly, but in the past GL himself has commented on the value disconnect a number of times.
If iclaprim had been approved at the first time of asking, I am pretty sure that these ATs would be all anyone would be talking about here now, because they probably would have killed any rerate, yet again, and you'd all be raging at them!!!
Anyone who disagrees with this, I suggest look at the ATs and the price action over the last year or so, or even just the last few months or even weeks, and continue to monitor them from this point forward. It's been so blatant it's ridiculous and makes a mockery of the market.
In spite of this I will still be partaking in any upcoming placing by Motif in order to average down, based on the belief that they already have the required data to obtain approval and the suspicion that the FDA used the CRL as a delay tactic as much as anything else. Once they receive approval, I am working on the notion that the ATs cannot stay in control forever, as surely whoever is behind them has an end game one way or another.
GLA.
Sign In
Follow the stocks
